Isolation and Bioactivity of Natural Products from <i>Streptomyces</i> sp. MA37
The isolation and characterization of bioactive metabolites from <i>Streptomyces</i> species continue to represent a vital area of research, given their potential in natural product drug discovery. In this study, we characterize a new siderophore called legonoxamine I, together with a kn...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Molecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1420-3049/30/2/306 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The isolation and characterization of bioactive metabolites from <i>Streptomyces</i> species continue to represent a vital area of research, given their potential in natural product drug discovery. In this study, we characterize a new siderophore called legonoxamine I, together with a known compound, streptimidone, from the talented soil bacterium <i>Streptomyces</i> sp. MA37, using chromatographic techniques and spectroscopic analysis. Legonoxamine I is a new holo-siderophore, which is likely to be a derailed product from the biosynthetic pathway of legonoxamine A. We also demonstrate that legonoxamine A possesses potent anticancer activity (IC<sub>50</sub> = 2.2 µM), exhibiting a remarkable ~30-fold increase in potency against MCF-7 ATCC HTB-22 breast cancer cells compared to desferrioxamine B, a structural analogue of legonoxamine A (IC<sub>50</sub> = 61.1 µM). Comparing the structural difference between legonoxamine A and desferrioxamine B, it is deduced that the phenylacetyl moiety in legonoxamine A may have contributed significantly to its enhanced potency. Our findings contribute to the growing library of <i>Streptomyces</i>-derived metabolites and underscore the genus’ potential as a promising source of lead compounds. |
|---|---|
| ISSN: | 1420-3049 |